HRs and 95% CIs for the association between patient characteristics and PFS
| . | . | Univariable model . | Multivariable model . | ||
|---|---|---|---|---|---|
| Patient characteristics . | N (event N) . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| Race and ethnicity | |||||
| Non-Hispanic White | 398 (249) | 1.00 (referent) | 1.00 (referent) | ||
| Non-Hispanic Black | 52 (36) | 0.83 (0.58, 1.19) | .3 | 0.95 (0.66, 1.37) | .8 |
| Hispanic | 45 (33) | 1.41 (0.98, 2.03) | .07 | 1.44 (0.98, 2.10) | .06 |
| Age at MM diagnosis* | 495 (318) | 1.01 (1.00, 1.02) | .2 | 1.00 (0.99, 1.01) | .6 |
| Sex | |||||
| Female | 206 (128) | 1.00 (referent) | 1.00 (referent) | ||
| Male | 289 (190) | 1.22 (0.97, 1.53) | .09 | 1.26 (1.00, 1.59) | .05 |
| ISS at MM diagnosis | |||||
| I | 190 (113) | 1.00 (referent) | 1.00 (referent) | ||
| II | 123 (75) | 1.25 (0.93, 1.68) | .1 | 1.23 (0.91, 1.66) | .2 |
| III | 111 (79) | 1.32 (0.99, 1.76) | .06 | 1.31 (0.97, 1.77) | .07 |
| Unknown | 71 (51) | 0.74 (0.53, 1.04) | .08 | 0.74 (0.52, 1.04) | .09 |
| HCT | |||||
| No HCT | 198 (113) | 1.00 (referent) | 1.00 (referent) | ||
| HCT | 297 (205) | 0.77 (0.61, 0.97) | .03 | N/A† | |
| Frontline treatment‡ | |||||
| PI + IMIDs | 197 (103) | 1.00 (referent) | 1.00 (referent) | ||
| PI | 165 (118) | 1.12 (0.86, 1.47) | .4 | 1.17 (0.89, 1.53) | .3 |
| IMIDs | 107 (73) | 0.77 (0.57, 1.05) | .1 | 0.83 (0.61, 1.14) | .2 |
| Others | 26 (24) | 0.61 (0.38, 1.00) | .05 | 0.69 (0.42, 1.14) | .2 |
| . | . | Univariable model . | Multivariable model . | ||
|---|---|---|---|---|---|
| Patient characteristics . | N (event N) . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| Race and ethnicity | |||||
| Non-Hispanic White | 398 (249) | 1.00 (referent) | 1.00 (referent) | ||
| Non-Hispanic Black | 52 (36) | 0.83 (0.58, 1.19) | .3 | 0.95 (0.66, 1.37) | .8 |
| Hispanic | 45 (33) | 1.41 (0.98, 2.03) | .07 | 1.44 (0.98, 2.10) | .06 |
| Age at MM diagnosis* | 495 (318) | 1.01 (1.00, 1.02) | .2 | 1.00 (0.99, 1.01) | .6 |
| Sex | |||||
| Female | 206 (128) | 1.00 (referent) | 1.00 (referent) | ||
| Male | 289 (190) | 1.22 (0.97, 1.53) | .09 | 1.26 (1.00, 1.59) | .05 |
| ISS at MM diagnosis | |||||
| I | 190 (113) | 1.00 (referent) | 1.00 (referent) | ||
| II | 123 (75) | 1.25 (0.93, 1.68) | .1 | 1.23 (0.91, 1.66) | .2 |
| III | 111 (79) | 1.32 (0.99, 1.76) | .06 | 1.31 (0.97, 1.77) | .07 |
| Unknown | 71 (51) | 0.74 (0.53, 1.04) | .08 | 0.74 (0.52, 1.04) | .09 |
| HCT | |||||
| No HCT | 198 (113) | 1.00 (referent) | 1.00 (referent) | ||
| HCT | 297 (205) | 0.77 (0.61, 0.97) | .03 | N/A† | |
| Frontline treatment‡ | |||||
| PI + IMIDs | 197 (103) | 1.00 (referent) | 1.00 (referent) | ||
| PI | 165 (118) | 1.12 (0.86, 1.47) | .4 | 1.17 (0.89, 1.53) | .3 |
| IMIDs | 107 (73) | 0.77 (0.57, 1.05) | .1 | 0.83 (0.61, 1.14) | .2 |
| Others | 26 (24) | 0.61 (0.38, 1.00) | .05 | 0.69 (0.42, 1.14) | .2 |
HR reflects the association of a 1-year increase in age at MM diagnosis with overall survival.
HCT violated the proportional hazard assumption and was included as a strata term in the multivariable model; therefore, no HR is provided for this variable.
For the majority of these regimens, patients were also given dexamethasone. Single-agent PIs and IMIDs were used rarely (<5%).